Shanghai, China, January 13, 2025 — Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women health with significant unmet medical needs, announced today the appointment of Ms. Helen Xu as Chief Commercial Officer. She will be fully responsible for the commercialization affairs of Asieris Pharmaceuticals and report to Dr. Kevin Pan, the founder, chairman and CEO of the company.
Ms. Helen Xu, Chief Commercial Officer, Asieris Pharmaceuticals
Helen has over 30 years of experience in commercial operations in the pharmaceutical industry, including more than 10 years in senior management positions. She has successfully overseen the launch of several groundbreaking innovative products such as Sutent (Sunitinib) and Elevit (prenatal vitamins). Prior to joining Asieris Pharmaceuticals, Helen served as the General Manager for the China region at Alfasigma, an Italian pharmaceutical group, where she led the company to become a top performer among European pharmaceutical companies in China, contributing to the group’s global market ranking in the top five. Before that, Helen held the position of Head of the Urology and Digestive Business Unit at Ferring Pharmaceuticals in China, where she achieved double-digit growth for three consecutive years through a robust product portfolio strategy. Helen has also held executive roles at major MNCs such as Pfizer, GSK, Roche, as well as domestic companies like Lvye and Hisun Pharmaceutical.
Dr. Kevin Pan stated, “We are very glad and delighted to welcome Helen to join Asieris. Helen has had a career spanning both multinational and local pharmaceutical companies. She has led teams to achieve important commercialization milestones such as the successful first launch of innovative drugs and rapid performance growth even in a highly competitive environment. She also has extensive comprehensive management experience in the commercialization field. We believe that Helen’s joining will rapidly strengthen the establishment of a comprehensive commercial system within the company and enhance our core competitiveness, accelerating our strategic goal of becoming a leading enterprise that integrates research and commercialization in our focused field.”
“Asieris is a rapidly growing global innovative pharmaceutical company with a diverse product pipeline that offers a competitive edge. I am honored to join Asieris and look forward to collaborating with the outstanding team members to drive the commercial progress of the company’s products swiftly, providing patients with more and better treatment options,” said Helen.
Helen holds a Medical Bachelor’s degree from Nanjing Medical University, an MBA degree certification from the China Europe International Business School (CEIBS), and a Marketing Management Certificate from the National University of Singapore.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
